Lowest Price Guaranteed
Pages
187
Last Updated
July 2026
View Count
5545
1. BACKGROUND
1.1. Context
1.2. Project Objectives
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
6.1. Overview of Cancer Metabolism Based Therapies
6.2. Key Metabolic Alterations Associated with Cancer Cells
6.3. Core Metabolic Pathways Associated with Cancer
6.4. Advantages of Cancer Metabolism Based Therapies
6.5. Challenges Associated with Cancer Metabolism Based Therapies
6.6. Future Outlook
7. MARKET LANDSCAPE
7.1. Methodology and Key Parameters
7.2. North America Cancer Metabolism Based Therapeutics: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Metabolic Pathway
7.2.3. Analysis by Target
7.2.4. Analysis by Target Disease Indication
7.2.5. Analysis by Route of Administration
7.2.6. Analysis by Type of Modality
7.2.7. Analysis by Type of Therapy
7.2.8. Analysis by Drug Designation
7.3. North America Cancer Metabolism Based Therapeutics: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Most Active Players: Analysis by Number of Therapies Developed
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Bristol Myers Squibb
8.2.1. Company Details
8.2.2. Cancer Metabolism Based Drugs Portfolio
8.2.3. Key Initiatives
8.3. Celcuity
8.4. Cornerstone Pharmaceuticals
8.5. Eli Lilly
8.6. IDEAYA Biosciences
8.7. Polaris
9. CLINICAL TRIAL ANALYSIS
9.1. Methodology and Key Parameters
9.2. North America Cancer Metabolism Based Therapeutics: Clinical Trial Analysis
9.2.1. Analysis by Trial Registration Year
9.2.2. Analysis by Trial Status
9.2.3. Analysis by Trial Registration Year and Trial Status
9.2.4. Analysis by Number of Patients Enrolled and Trial Registration Year
9.2.5. Analysis by Number of Patients Enrolled and Trial Status
9.2.6. Analysis by Trial Phase
9.2.7. Analysis by Number of Patients Enrolled and Trial Phase
9.2.8. Analysis by Study Design
9.2.8.1. Analysis by Design Masking
9.2.8.2. Analysis by Type of Intervention Model
9.2.8.3. Analysis by Trial Purpose
9.2.8.4. Analysis by Type of Allocation
9.2.9. Analysis by Type of Sponsor / Collaborator
9.2.10. Analysis by Patient Gender
9.2.11. Most Active Industry Players: Analysis by Number of Clinical Trials
9.2.12. Most Active Non-Industry Players: Analysis by Number of Clinical Trials
9.2.13. Geographical Distribution of Trials and Number of Patients Enrolled
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Partnership Models
10.2. North America Cancer Metabolism Based Therapeutics: Partnerships and Collaborations
10.2.1. Analysis by Year of Partnership
10.2.2. Analysis by Type of Partnership
10.2.3. Analysis by Year and Type of Partnership
10.2.4. Analysis by Target Disease Indication
10.2.5. Most Active Players: Analysis by Number of Partnerships
10.2.6. Analysis by Geography
10.2.6.1. Local and International Deals
10.2.6.2. Intercontinental and Intracontinental Deals
11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
12. NORTH AMERICA CANCER METABOLISM BASED THERAPEUTICS MARKET
12.1. Chapter Overview
12.2. Key Assumptions
12.3. Forecast Methodology
12.4. North America Cancer Metabolism Based Therapeutics Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
12.5. Multivariate Scenario Analysis
12.5.1. North America Cancer Metabolism Based Therapeutics Market, Forecasted Estimates (Till 2035), Conservative Scenario
12.5.2. North America Cancer Metabolism Based Therapeutics Market, Forecasted Estimates (Till 2035), Optimistic Scenario
12.6. Key Market Segmentations
13. NORTH AMERICA CANCER METABOLISM BASED THERAPEUTICS MARKET, BY TYPE OF MODALITY
13.1. North America Cancer Metabolism Based Therapeutics Market: Distribution by Type of Modality
13.1.1. North America Cancer Metabolism Based Therapeutics Market for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
13.1.2. North America Cancer Metabolism Based Therapeutics Market for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
13.2. Data Triangulation and Validation
14. NORTH AMERICA CANCER METABOLISM BASED THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
14.1. North America Cancer Metabolism Based Therapeutics Market: Distribution by Route of Administration
14.1.1. North America Cancer Metabolism Based Therapeutics Market for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
14.1.2. North America Cancer Metabolism Based Therapeutics Market for Intramuscular Route: Forecasted Estimates (Till 2035)
14.1.3. North America Cancer Metabolism Based Therapeutics Market for Intravenous Route: Forecasted Estimates (Till 2035)
14.2. Data Triangulation and Validation
15. NORTH AMERICA CANCER METABOLISM BASED THERAPEUTICS MARKET, BY TARGET DISEASE INDICATION
15.1. North America Cancer Metabolism Based Therapeutics Market: Distribution by Target Disease Indication
15.1.1. North America Cancer Metabolism Based Therapeutics Market for Breast Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.2. North America Cancer Metabolism Based Therapeutics Market for Non-small Cell Lung Cancer: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.3. North America Cancer Metabolism Based Therapeutics Market for Acute Myeloid Leukemia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.4. North America Cancer Metabolism Based Therapeutics Market for Brain Cancer: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)
15.1.5. North America Cancer Metabolism Based Therapeutics Market for Cholangiocarcinoma: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.6. North America Cancer Metabolism Based Therapeutics Market for Bile Duct Cancer: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.1.7. North America Cancer Metabolism Based Therapeutics Market for Myelodysplastic Syndromes: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
15.1.8. North America Cancer Metabolism Based Therapeutics Market for Malignant-mesothelioma: Forecasted Estimates (Till 2035)
15.1.9. North America Cancer Metabolism Based Therapeutics Market for Pancreatic Cancer: Forecasted Estimates (Till 2035)
15.1.10. North America Cancer Metabolism Based Therapeutics Market for Soft Tissue Sarcoma: Forecasted Estimates (Till 2035)
15.1.11. North America Cancer Metabolism Based Therapeutics Market for Hepatocellular Carcinoma: Forecasted Estimates (Till 2035)
15.2. Data Triangulation and Validation
16. NORTH AMERICA CANCER METABOLISM BASED THERAPEUTICS MARKET, SALES FORECAST OF DRUGS
16.1. Approved Cancer Metabolism Based Therapies: Sales Forecast
16.1.1. Daraxonrasib: Sales Forecast
16.1.2. Gedatolisib: Sales Forecast
16.1.3. Olomorasib: Sales Forecast
16.1.4. Inavolisib: Sales Forecast
16.1.5. Vorasidenib: Sales Forecast
16.1.6. STX-478: Sales Forecast
16.1.7. AZD 5363: Sales Forecast
16.1.8. AG-120: Sales Forecast
16.1.9. Selpercatinib: Sales Forecast
16.1.10. ADI-PEG 20: Sales Forecast
16.1.11. Augtyro: Sales Forecast
16.1.12. Taletrectinib: Sales Forecast
16.1.13. Piqray / Vijoice: Sales Forecast
16.1.14. TAS-120: Sales Forecast
16.1.15. Rezlidhia: Sales Forecast
16.1.16. AG-221: Sales Forecast
17. CONCLUDING REMARKS
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Company A
18.2.1. Company Snapshot
18.2.2. Interview Transcript: President and Chief Executive Officer
18.3. Company B
18.3.1. Company Snapshot
18.3.2. Interview Transcript President and Chief Executive Officer
18.4. Company C
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Chief Executive Officer
18.5. Company D
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Chief Financial Officer
18.6. Company E
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Associate Professor
18.7. Company F
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Medical Oncologist
18.8. Company G
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Associate Professor
18.9. Company H
18.9.1. Company Snapshot
18.9.2. Interview Transcript: Former Vice President, Head of Research and Translational Sciences
18.10. Company I
18.10.1. Company Snapshot
18.10.2. Interview Transcript: Postdoctoral Researcher
18.11. Interview Transcript: Consultant Dietitian
19. APPENDIX I: TABULATED DATA
20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS